Depletion of Ikaros, Aiolos, and CK1α is particularly toxic for malignant cells in hematological cancers, accounting for FDA approval of thalidomide-like drugs for multiple myeloma [61,126]. This evidence concerns the gene CSNK1A1 and hematopoietic and lymphoid cell neoplasm.